SG11202009876TA - Stable formulations of therapeutic antibody - Google Patents
Stable formulations of therapeutic antibodyInfo
- Publication number
- SG11202009876TA SG11202009876TA SG11202009876TA SG11202009876TA SG11202009876TA SG 11202009876T A SG11202009876T A SG 11202009876TA SG 11202009876T A SG11202009876T A SG 11202009876TA SG 11202009876T A SG11202009876T A SG 11202009876TA SG 11202009876T A SG11202009876T A SG 11202009876TA
- Authority
- SG
- Singapore
- Prior art keywords
- therapeutic antibody
- stable formulations
- formulations
- stable
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841013647 | 2018-04-10 | ||
| PCT/IN2019/050293 WO2019198101A1 (en) | 2018-04-10 | 2019-04-10 | Stable formulations of therapeutic antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009876TA true SG11202009876TA (en) | 2020-11-27 |
Family
ID=68164106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009876TA SG11202009876TA (en) | 2018-04-10 | 2019-04-10 | Stable formulations of therapeutic antibody |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210401982A1 (en) |
| EP (1) | EP3773696A4 (en) |
| JP (1) | JP2021521171A (en) |
| CN (1) | CN112292146A (en) |
| AU (1) | AU2019251453A1 (en) |
| BR (1) | BR112020020703A2 (en) |
| CO (1) | CO2020013571A2 (en) |
| SG (1) | SG11202009876TA (en) |
| WO (1) | WO2019198101A1 (en) |
| ZA (1) | ZA202006264B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021521168A (en) * | 2018-04-10 | 2021-08-26 | ドクター レディズ ラボラトリーズ リミテッド | Stable antibody preparation |
| WO2022253994A1 (en) * | 2021-06-04 | 2022-12-08 | Polpharma Biologics S.A. | Vedolizumab formulation |
| WO2023126411A1 (en) * | 2021-12-27 | 2023-07-06 | Polpharma Biologics S.A. | Vedolizumab formulation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| KR101247418B1 (en) * | 2007-12-21 | 2013-03-25 | 에프. 호프만-라 로슈 아게 | Antibody formulation |
| CN108969469A (en) * | 2011-05-02 | 2018-12-11 | 米伦纽姆医药公司 | The preparation of 4 β of anti alpha, 7 antibody |
| UA116189C2 (en) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | FORMULATION FOR ANTI-α4β7 ANTIBODY |
-
2019
- 2019-04-10 SG SG11202009876TA patent/SG11202009876TA/en unknown
- 2019-04-10 AU AU2019251453A patent/AU2019251453A1/en not_active Abandoned
- 2019-04-10 WO PCT/IN2019/050293 patent/WO2019198101A1/en unknown
- 2019-04-10 JP JP2020555466A patent/JP2021521171A/en active Pending
- 2019-04-10 EP EP19785714.7A patent/EP3773696A4/en active Pending
- 2019-04-10 BR BR112020020703-9A patent/BR112020020703A2/en unknown
- 2019-04-10 US US17/045,406 patent/US20210401982A1/en active Pending
- 2019-04-10 CN CN201980038006.9A patent/CN112292146A/en active Pending
-
2020
- 2020-10-08 ZA ZA2020/06264A patent/ZA202006264B/en unknown
- 2020-10-28 CO CONC2020/0013571A patent/CO2020013571A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2020013571A2 (en) | 2021-01-18 |
| US20210401982A1 (en) | 2021-12-30 |
| JP2021521171A (en) | 2021-08-26 |
| BR112020020703A2 (en) | 2021-01-12 |
| WO2019198101A1 (en) | 2019-10-17 |
| EP3773696A4 (en) | 2021-12-29 |
| AU2019251453A1 (en) | 2020-11-26 |
| CN112292146A (en) | 2021-01-29 |
| AU2019251453A2 (en) | 2020-12-03 |
| ZA202006264B (en) | 2022-09-28 |
| EP3773696A1 (en) | 2021-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279464A (en) | Pharmaceutical formulation of odevixibat | |
| IL272410A (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
| ZA202006264B (en) | Stable formulations of therapeutic antibody | |
| IL278041A (en) | Buffered formulations of bevacizumab for use of treating diseases | |
| IL275639A (en) | Formulation for administration of rna | |
| IL286100A (en) | Anti-il-36r antibody formulations | |
| IL278151A (en) | Formulations of human anti-pd-l1 antibodies | |
| IL277943A (en) | Stable anti-cd79b immunoconjugate formulations | |
| ZA202006570B (en) | Pharmaceutical formulations | |
| IL285134A (en) | Therapeutic antibody formulation | |
| IL281976A (en) | Anti-fgfr2 antibody formulations | |
| IL279622A (en) | Pharmaceutical formulations of masked antibodies | |
| IL291131A (en) | Anti-il-23p19 antibody formulations | |
| EP3313520A4 (en) | Therapeutic uses of berberine formulations | |
| IL272857A (en) | Formulations of copanlisib | |
| EP3525772A4 (en) | Formulations for enteric delivery of therapeutic agents | |
| IL283593A (en) | Oral formulations of branaplam | |
| IL283886A (en) | Antibody formulations | |
| IL280906A (en) | Formulations of ag10 | |
| IL269424B1 (en) | New therapeutical use of h3-ligands | |
| IL267279A (en) | Pharmaceutical formulations of suvorexant | |
| EP3810118A4 (en) | Formulations of tegavivint and related compounds | |
| SG11202010792TA (en) | Improved pharmaceutical formulations | |
| PT3678644T (en) | Formulations of copanlisib | |
| IL289338A (en) | Therapeutic interactions of leucomethylthioninium |